Cerebral Palsy (CP) is a disabling condition that affects a child's life and his/her family irreversibly. It is usually a non-progressive condition but improvement over time is rarely seen. The condition can be due to prenatal hypoxia, metabolic, genetic, infectious, traumatic or other causes. It is therefore a heterogeneous group that results in functional motor disability associated with different degrees of cognitive abnormalities. There are no treatments that can cure or even improve CP and the best available approach aims at functional, social and nutritional supportive care and counseling. In this paper, we report 17 sequential patients with CP treated with intrathecal administration of Bone Marrow Mononuclear Cells (BMMC). All patients had an uneventful post-injection course with 73% of the evaluable patients treated having a good response using the Gross Motor Function Classification System (GMFCS). The average improvement was 1.3 levels on the GMFCS with cognitive improvements as well.

中文翻译：

---

干细胞治疗脑瘫：17 例报告。

脑瘫 (CP) 是一种致残性疾病，会不可逆转地影响儿童及其家庭的生活。它通常是一种非进展性疾病，但随着时间的推移很少见改善。这种情况可能是由于产前缺氧、代谢、遗传、感染、创伤或其他原因造成的。因此，这是一个异质群体，导致与不同程度的认知异常相关的功能性运动障碍。没有任何治疗方法可以治愈甚至改善脑瘫，最好的可用方法旨在功能、社会和营养支持护理和咨询。在本文中，我们报道了 17 例连续接受鞘内注射骨髓单核细胞 (BMMC) 治疗的 CP 患者。所有患者的注射后过程都很顺利，73% 的可评估患者使用粗大运动功能分类系统 (GMFCS) 获得了良好的反应。GMFCS 的平均改善为 1.3 个水平，认知能力也得到改善。